ROS1 and non-small cell lung carcinoma: ROS1 fusions occur in 1%–2% of NSCLC, and the prevalence is higher among patients in Asian countries (including China) than in Western countries (Cai and Su, 2013; Davies and Doebele, 2013; Melosky et al., 2021).